Eto Kimika, Tsuchihashi Takuya, Abe Isao, Iida Mitsuo
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University.
Nihon Ronen Igakkai Zasshi. 2002 Mar;39(2):181-6. doi: 10.3143/geriatrics.39.181.
We examined the effect and safety of combination therapy with low-dose diuretics (hydrochlorothiazide: HCTZ) and angiotensin II receptor antagonist (losartan) in elderly cases of hypertension, using ambulatory blood pressure monitoring (ABPM). Elderly hypertensive patients (mean age 75 +/- 2 years) were treated with either losartan (25-50 mg/day) or HCTZ (12.5 mg/day) for at least 4 weeks, and then 24-hour blood pressure (BP) was measured by ABPM. Combination therapy with addition of other drug was initiated in 14 patients whose 24-hour systolic BP or daytime systolic BP was over 140 mmHg (160 mmHg for the patients of 80 years or older). After 4 weeks of the combination therapy, ABPM was repeated. Blood cell count and blood chemistry were also done before and after initiation of combination therapy. In the losartan-preceding group (n = 9), the combination therapy with HCTZ reduced 24-hour BP by 19.3 +/- 2.3/6.6 +/- 2.3 mmHg. Similarly, daytime and nighttime BP decreased by 21.4 +/- 4/8.4 +/- 2.8 mmHg and 15.2 +/- 4/4.2 +/- 2.4 mmHg, respectively. In the HCTZ-preceding group, the combination with losartan also decreased 24-hour BP by 12.2 +/- 4.8/3.4 +/- 1.4 mmHg. The decreases of daytime and nighttime BP were 13.8 +/- 6.6/4 +/- 1.1 mmHg and 10 +/- 4.7/3 +/- 2.4 mmHg, respectively. Heart rate did not change with combination therapy in the losartan-preceding group, while heart rate during daytime tended to decrease by addition of losartan in the HCTZ-preceding group (3.8 +/- 1.7/min). Serum electrolytes, uric acid, lipids, renal function and body weight did not change during the study period. Thus, combination therapy of losartan/hydrochlorothiazide seems useful in the treatment of elderly hypertension, showing additive BP lowering effect without metabolic adverse effects.
我们采用动态血压监测(ABPM),研究了小剂量利尿剂(氢氯噻嗪:HCTZ)与血管紧张素II受体拮抗剂(氯沙坦)联合治疗老年高血压患者的疗效及安全性。老年高血压患者(平均年龄75±2岁)接受氯沙坦(25 - 50毫克/天)或氢氯噻嗪(12.5毫克/天)治疗至少4周,然后通过ABPM测量24小时血压(BP)。对14例24小时收缩压或日间收缩压超过140毫米汞柱(80岁及以上患者为160毫米汞柱)的患者开始加用其他药物的联合治疗。联合治疗4周后,重复进行ABPM。在开始联合治疗前后还进行了血细胞计数和血液生化检查。在氯沙坦先行组(n = 9)中,氢氯噻嗪联合治疗使24小时血压降低了19.3±2.3/6.6±2.3毫米汞柱。同样,日间和夜间血压分别降低了21.4±4/8.4±2.8毫米汞柱和15.2±4/4.2±2.4毫米汞柱。在氢氯噻嗪先行组中,与氯沙坦联合治疗也使24小时血压降低了12.2±4.8/3.4±1.4毫米汞柱。日间和夜间血压的降低分别为13.8±6.6/4±1.1毫米汞柱和10±4.7/3±2.4毫米汞柱。氯沙坦先行组联合治疗时心率未改变,而在氢氯噻嗪先行组中加用氯沙坦后日间心率有下降趋势(3.8±1.7次/分钟)。在研究期间血清电解质、尿酸、血脂及肾功能和体重均未改变。因此,氯沙坦/氢氯噻嗪联合治疗对老年高血压的治疗似乎有效,显示出相加的降压效果且无代谢不良反应。